CompareMarketResearchRequest a sample
Home / Healthcare / Peptide Receptor Radionuclide Therapy (PRRT)

Healthcare · Market report

Peptide Receptor Radionuclide Therapy (PRRT) Market Size, Share and Forecast 2026-2036

The global peptide receptor radionuclide therapy (PRRT) market is worth USD 913 mn in 2026 and is forecast to reach USD 2.0 bn by 2036, growing at a 8.0% CAGR. United States is the largest country market and Lutetium-177 dotatate (existing) is the largest by product segment.

USD 913 mnMarket size 2026
USD 2.0 bnForecast 2036
8.0%CAGR 2026-2036
United StatesLargest country

Request a free sample Jump to the forecast

Report price: Starts from USD 1,999

5 segmentation views25 countries2026 to 2036 yearly forecast

Market overview

The global peptide receptor radionuclide therapy (PRRT) market is worth USD 913 mn in 2026 and is forecast to reach USD 2.0 bn by 2036, growing at a 8.0% CAGR. United States is the largest country market and Lutetium-177 dotatate (existing) is the largest by product segment.

ScopeLutetium-based radioligand treatment for somatostatin receptor positive neuroendocrine tumours, delivered as intravenous radiopharmaceutical doses at nuclear medicine centres.
IndustryHealthcare
Value 2025USD 830 mn
Value 2026USD 913 mn
Value 2036USD 2.0 bn
CAGR 2026-20368.0%
Volume 202618.9 thousand doses
Volume 203645.1 thousand doses
Average price 2026USD 48,340 per dose
Report priceStarts from USD 1,999
PublishedNovember 2026

Request a free sample of this report

Peptide Receptor Radionuclide Therapy (PRRT) market size and forecast, 2026-2036

Exhibit 1The global peptide receptor radionuclide therapy (PRRT) market is forecast to grow from USD 913 mn in 2026 to USD 2.0 bn by 2036, more than doublingGlobal market value in USD: 2025 base year, 2026 estimate and forecast to 2036. CAGR 2026 to 2036: 8.0%
Peptide Receptor Radionuclide Therapy (PRRT) market value, 2025 to 2036Market value by year. 2025: USD 830.0 mn; 2026: USD 913.0 mn; 2027: USD 986.0 mn; 2028: USD 1.06 bn; 2029: USD 1.15 bn; 2030: USD 1.24 bn; 2031: USD 1.34 bn; 2032: USD 1.45 bn; 2033: USD 1.56 bn; 2034: USD 1.69 bn; 2035: USD 1.83 bn; 2036: USD 1.97 bn. Compound annual growth rate 2026 to 2036: 8.0%.2025913.0 mn20261.34 bn20311.97 bn20368.0% CAGR

Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.

YearMarket value
2026USD 913.0 mn
2027USD 986.0 mn
2028USD 1.06 bn
2029USD 1.15 bn
2030USD 1.24 bn
2031USD 1.34 bn
2032USD 1.45 bn
2033USD 1.56 bn
2034USD 1.69 bn
2035USD 1.83 bn
2036USD 1.97 bn

Peptide Receptor Radionuclide Therapy (PRRT) market segmentation

By product

Exhibit 2Lutetium-177 dotatate (existing) is the largest segment by product, with 90.0% of 2026 revenueEstimated share of 2026 global revenue, by product
Peptide Receptor Radionuclide Therapy (PRRT) market share by product, 2026Share of 2026 revenue by product. Lutetium-177 dotatate (existing): 90.0%; Next-generation dotatate and edotreotide agents: 7.0%; Other radioligands: 3.0%.Lutetium-177 dotatate (existing)90.0%Next-generation dotatate and edotreotide agents7.0%Other radioligands3.0%

Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.

SegmentShare 2026Share 2036Value 2026CAGR 2026-36
Lutetium-177 dotatate (existing)90.0%61.4%USD 822 mn4.0%
Next-generation dotatate and edotreotide agents7.0%31.5%USD 64 mn25.5%
Other radioligands3.0%7.1%USD 27 mn17.7%

By tumour origin

Exhibit 3Gastroenteropancreatic adds the most revenue by tumour origin, growing from USD 639 mn in 2026 to USD 1.4 bn by 2036Estimated revenue in USD by tumour origin, 2026 and 2036 forecast
Peptide Receptor Radionuclide Therapy (PRRT) market by tumour origin, 2026 and 2036Revenue by tumour origin in 2026 and 2036. Gastroenteropancreatic: USD 639 mn in 2026, USD 1.4 bn in 2036, change +112%; Lung and other neuroendocrine: USD 164 mn in 2026, USD 364 mn in 2036, change +122%; Pheochromocytoma and paraganglioma: USD 110 mn in 2026, USD 254 mn in 2036, change +132%.20262036 forecastChangeGastroenteropancreatic+112%639 mn1.4 bnLung and other neuroendocrine+122%164 mn364 mnPheochromocytoma and paraganglioma+132%110 mn254 mn

Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.

SegmentShare 2026Share 2036Value 2026CAGR 2026-36
Gastroenteropancreatic70.0%68.6%USD 639 mn7.8%
Lung and other neuroendocrine18.0%18.5%USD 164 mn8.3%
Pheochromocytoma and paraganglioma12.0%12.9%USD 110 mn8.8%

By end use

SegmentShare 2026Share 2036Value 2026CAGR 2026-36
General hospitals50.0%49.3%USD 456 mn7.9%
Specialty nuclear medicine centres28.0%28.9%USD 256 mn8.4%
Comprehensive cancer centres22.0%21.7%USD 201 mn7.9%

By radionuclide

SegmentShare 2026Share 2036Value 2026CAGR 2026-36
Lutetium-17764.0%62.0%USD 584 mn7.7%
Yttrium-9018.0%14.0%USD 164 mn5.3%
Actinium-225 and new alpha emitters18.0%24.0%USD 164 mn11.2%

By treatment stage

SegmentShare 2026Share 2036Value 2026CAGR 2026-36
Newly approved indications34.0%34.0%USD 310 mn8.0%
Established indications46.0%40.0%USD 420 mn6.5%
Clinical trial use20.0%26.0%USD 183 mn10.9%

Top 25 countries for peptide receptor radionuclide therapy (PRRT) by revenue

Countries are ranked by revenue earned from sales in the country, not by where the product is made. The ten largest hold 94.0% of 2026 revenue and the 25 countries below together hold 98.2%.

Exhibit 4United States is the largest country market at USD 511 mn in 2026, and the three largest countries hold 70.0% of global revenueEstimated 2026 revenue in USD and share of the global market, ten largest countries
Peptide Receptor Radionuclide Therapy (PRRT) market, ten largest countries in 2026Ten largest countries by 2026 revenue. United States: USD 511 mn, 56.0%; Germany: USD 73 mn, 8.0%; Japan: USD 55 mn, 6.0%; France: USD 46 mn, 5.0%; Italy: USD 37 mn, 4.0%; United Kingdom: USD 37 mn, 4.0%; Spain: USD 32 mn, 3.5%; Netherlands: USD 27 mn, 3.0%; Canada: USD 23 mn, 2.5%; Australia: USD 18 mn, 2.0%.United States511 mn 56.0%Germany73 mn 8.0%Japan55 mn 6.0%France46 mn 5.0%Italy37 mn 4.0%United Kingdom37 mn 4.0%Spain32 mn 3.5%Netherlands27 mn 3.0%Canada23 mn 2.5%Australia18 mn 2.0%

Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.

#CountryValue 2026Share 2026Value 2036CAGR 2026-36
1United StatesUSD 511 mn56.0%USD 1.1 bn7.9%
2GermanyUSD 73 mn8.0%USD 156 mn7.9%
3JapanUSD 55 mn6.0%USD 134 mn9.4%
4FranceUSD 46 mn5.0%USD 97 mn7.8%
5ItalyUSD 37 mn4.0%USD 79 mn8.0%
6United KingdomUSD 37 mn4.0%USD 79 mn8.0%
7SpainUSD 32 mn3.5%USD 69 mn8.0%
8NetherlandsUSD 27 mn3.0%USD 59 mn8.0%
9CanadaUSD 23 mn2.5%USD 49 mn8.0%
10AustraliaUSD 18 mn2.0%USD 43 mn9.0%
11South KoreaUSD 6.3 mn0.7%USD 13 mn7.8%
12BrazilUSD 5.3 mn0.6%USD 11 mn7.8%
13SwitzerlandUSD 4.8 mn0.5%USD 10 mn7.8%
14SwedenUSD 4.2 mn0.5%USD 8.9 mn7.8%
15AustriaUSD 3.6 mn0.4%USD 7.5 mn7.7%
16BelgiumUSD 2.7 mn0.3%USD 5.9 mn8.0%
17DenmarkUSD 2.4 mn0.3%USD 5.1 mn8.0%
18IsraelUSD 1.9 mn0.2%USD 4.1 mn8.0%
19PolandUSD 1.6 mn0.2%USD 3.4 mn8.0%
20IndiaUSD 1.3 mn0.1%USD 2.8 mn8.0%
21TurkeyUSD 1.2 mn0.1%USD 2.6 mn8.0%
22TaiwanUSD 1.0 mn0.1%USD 2.2 mn8.0%
23MexicoUSD 0.82 mn0.09%USD 1.6 mn6.7%
24IrelandUSD 0.64 mn0.07%USD 1.4 mn8.0%
25SingaporeUSD 0.64 mn0.07%USD 1.2 mn6.3%
Rest of worldUSD 16 mn1.8%USD 33 mn7.2%
Exhibit 5United States and Germany account for 63% of the USD 1.1 bn the market is forecast to add by 2036Forecast revenue added between 2026 and 2036 by country, in USD
Peptide Receptor Radionuclide Therapy (PRRT) market, where the growth to 2036 comes fromRevenue added between 2026 and 2036. Market value 2026: USD 913 mn. United States: +USD 581 mn; Germany: +USD 83 mn; Japan: +USD 79 mn; France: +USD 51 mn; Italy: +USD 42 mn; 20 other countries: +USD 206 mn; Rest of world: +USD 16 mn. Market value 2036: USD 2.0 bn.Market value 2026913 mnUnited States+581 mnGermany+83 mnJapan+79 mnFrance+51 mnItaly+42 mn20 other countries+206 mnRest of world+16 mnMarket value 20362.0 bn

Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.

Competitive landscape

Group 1: Global leaders

  • Novartis

Group 2: Regional and specialist players

  • Curium
  • ITM Isotope Technologies Munich
  • Orano Med
  • Eckert and Ziegler
  • SHINE Technologies
  • Jubilant Radiopharma

Group 3: Emerging and niche players

  • RayzeBio
  • Perspective Therapeutics
  • Clarity Pharmaceuticals
  • Isotopia Molecular Imaging

Research methodology

Every figure on this page comes from the research framework that we apply to all of the markets we cover. The 2025 base for the peptide receptor radionuclide therapy (PRRT) market is built from the volume sold and the price that buyers pay, and is cross-checked against the size of the wider industry the market belongs to. Where a market can be sized in more than one way, the routes are compared before a figure is set.

The forecast runs year by year from the 2025 base to 2036. Growth in each year reflects demand from the industries that buy the product, adoption of new technology, pricing, regulation and replacement cycles. Volume and price are modelled together, so revenue in each year equals volume multiplied by average price. The 2026 to 2036 compound annual growth rate of 8.0% is calculated from the resulting values.

The market is divided by product, by tumour origin, by end use, by radionuclide, by treatment stage. The 25 largest countries are ranked by revenue earned from sales to buyers in each country, not by where the product is made. Segment values and country values add up to the market total in every year, and every report is checked for consistency before it is published.

Companies are placed in three groups: global leaders, regional and specialist players, and emerging and niche players. The groups describe how companies compete in the market. They are not a ranking and they are not market shares.

Our analysts also carry out primary research. Customized reports add interviews with key opinion leaders, such as senior executives, technical specialists and buyers, to test the assumptions behind the numbers for the question being asked.

Read the full research methodology

Frequently asked questions

How big is the peptide receptor radionuclide therapy (PRRT) market?

The global peptide receptor radionuclide therapy (PRRT) market is estimated at USD 830 mn in 2025 and USD 913 mn in 2026.

How fast will the peptide receptor radionuclide therapy (PRRT) market grow?

It is forecast to reach USD 2.0 bn by 2036, a compound annual growth rate of 8.0% from 2026, an increase of USD 1.1 bn.

Which country is the largest market for peptide receptor radionuclide therapy (PRRT)?

United States is the largest market by revenue at USD 511 mn in 2026, 56.0% of the global total. The three largest countries together hold 70.0%.

Which country is growing fastest?

Among the ten largest markets, Japan is growing fastest at 9.4% a year from 2026 to 2036.

Which peptide receptor radionuclide therapy (PRRT) segment is largest?

In the by product split, Lutetium-177 dotatate (existing) is the largest segment with 90.0% of 2026 revenue.

Who are the leading peptide receptor radionuclide therapy (PRRT) companies?

Global leaders include Novartis.

Need the full report?

Request a sample to see the structure, tables and country detail.

Request a free sample

Related markets in Healthcare

← Pen Injector Peptide Therapeutics →

All Healthcare markets →

Request a sample